Latest Ratios: P/E Ratio -9.0x · EV/EBITDA N/A · ROE -60.3%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $570M | $254M | $61M | $304M | $97M | $358M | $2.2B | — | — |
| Enterprise Value | $518M | $202M | $7M | $182M | $55M | $265M | $2.0B | — | — |
| P/E Ratio → | -9.01 | — | — | — | — | — | — | — | — |
| P/S Ratio | 570.25 | 253.99 | 10.74 | 183.31 | 149.50 | 11.92 | 220.36 | — | — |
| P/B Ratio | 5.33 | 3.08 | 0.77 | 2.10 | 0.55 | 1.32 | 7.06 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 202.21 | 1.30 | 110.03 | 84.35 | 8.84 | 204.46 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -195.1% | -195.1% | 14.5% | -143.9% | -12507.2% | 95.4% | -277.3% | -195.5% | -10.5% |
| Operating Margin | -5150.8% | -5150.8% | -1408.3% | -5549.6% | -15848.0% | -150.8% | -371.8% | -253.5% | -27.4% |
| Net Profit Margin | -4880.9% | -4880.9% | -1318.1% | -5268.4% | -15635.7% | -149.8% | -368.5% | -242.6% | -32.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -60.3% | -60.3% | -67.2% | -54.4% | -45.5% | -15.5% | -26.6% | — | — |
| ROA | -53.6% | -53.6% | -60.2% | -47.8% | -40.5% | -13.9% | -18.6% | -42.4% | -10.8% |
| ROIC | -137.3% | -137.3% | -247.0% | -87.9% | -49.5% | -20.5% | -50.2% | — | — |
| ROCE | -62.0% | -62.0% | -70.0% | -56.0% | -45.5% | -14.9% | -20.7% | -69.3% | -13.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.63 | -0.68 | -0.84 | -0.24 | -0.34 | -0.51 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -1.81 |
Net cash position: cash ($54M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.70 | 11.70 | 8.88 | 12.51 | 7.39 | 11.72 | 20.53 | 2.12 | 3.15 |
| Quick Ratio | 11.70 | 11.70 | 8.88 | 12.51 | 7.39 | 11.72 | 20.53 | 2.12 | 3.15 |
| Cash Ratio | 11.07 | 11.07 | 8.19 | 11.41 | 6.46 | 10.93 | 19.93 | 1.96 | 2.90 |
| Asset Turnover | — | 0.01 | 0.06 | 0.01 | 0.00 | 0.10 | 0.03 | 0.22 | 0.33 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $70M | $51M | $43M | $42M | $42M | $42M | $42M | $15M |
Includes 30+ ratios · 8 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying STTK stock.
Shattuck Labs, Inc.'s current P/E ratio is -9.0x. This places it at the 50th percentile of its historical range.
Shattuck Labs, Inc.'s return on equity (ROE) is -60.3%. The historical average is -44.9%.
Based on historical data, Shattuck Labs, Inc. is trading at a P/E of -9.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Shattuck Labs, Inc. has -195.1% gross margin and -5150.8% operating margin.
Key Metrics
Top Statement Risk
Cash runway with no revenue
Metrics are mathematically derived from official filings.
Valuation Reflects Pure Speculative Premium
Shattuck's P/S ratio of 691.35x and P/B of 6.46x represent extreme premiums for a company with no meaningful revenue, as reported in its latest financial statements, pricing in entirely speculative future pipeline successes.
The valuation multiples are functionally irrelevant for traditional analysis given the near-zero revenue base, with the P/S ratio inflated to an astronomical level. The P/B of 6.46x, while high, is less extreme and likely reflects the market's valuation of the company's remaining cash and intellectual property portfolio. These multiples imply the stock is priced as a call option on successful clinical outcomes rather than as an operating business.
High Liquidity Masks Accelerating Burn
Despite an extremely high current and quick ratio of 27.59 in 2026Q2, based on the company's reported balance sheet, the quarterly cash burn of approximately $27 million suggests the liquidity cushion provides a finite runway.
The current ratio has ballooned from 7.62x in 2024Q2 to 27.59x, driven by a capital raise that boosted cash reserves. However, this static snapshot is misleading without considering the dynamic burn rate. The absence of inventory makes the quick ratio identical to the current ratio, but this liquidity is being rapidly consumed by operating losses, meaning the high ratio does not equate to operational strength.
Minimal Leverage Reflects Equity-Funded Model
Shattuck's debt-to-equity ratio of 0.01 in 2026Q2, as noted in the financial data, indicates the company's operations are funded almost entirely through equity issuances, avoiding debt service obligations.
The negligible leverage is a direct consequence of the company's stage; it lacks the revenue or EBITDA to support meaningful debt, as evidenced by the negative and unavailable D/EBITDA and interest coverage metrics. This capital structure minimizes financial risk in the near term but results in ongoing shareholder dilution. The absence of debt covenants is a positive, but the reliance on equity markets for continued funding is a primary risk.
Most Misapplied Ratio: Price-to-Sales
The P/S ratio of 691.35x is the most misapplied metric for Shattuck Labs, as it is based on a residual revenue figure that does not reflect the company's core operational reality or future potential.
Applying a P/S multiple is fundamentally flawed for a pre-commercial biotech with near-zero revenue, as it creates a misleadingly high figure that obscures the actual investment thesis, which is based on pipeline value. Investors should instead focus on cash position relative to burn rate to estimate runway, and on qualitative clinical milestones, rather than traditional valuation multiples. The P/S ratio here provides no useful signal about relative value or growth expectations.